- Findings using data from 2 large independent population‐based studies suggest that statin use is associated with reduced risk for primary liver cancer.
- This inverse association was only evident for hepatocellular carcinoma (HCC) and not intrahepatic bile duct carcinoma (IBDC) in the UK Biobank analysis.
Why this matters
- Epidemiological studies examining the association of statin use and the risk for liver cancer have shown conflicting results.
- Study evaluated the association between the use of statins and the risk for primary liver cancer using data from 2 well-designed, large independent data sets from the UK (Scottish Primary Care Clinical Informatics Unit [PCCIU] database and the UK Biobank).
- Funding: None disclosed.
- PCCIU case-control analysis:
- 434 liver cancer cases were matched to 2103 control participants.
- The risk for liver cancer was 39% lower with statin use over a median exposure period of 4.8 years (adjusted OR, 0.61; 95% CI, 0.43-0.87).
- Prospective cohort study within the UK Biobank:
- Among 471,851 participants, 182 participants developed incident liver cancer (HCC, 88; IBDC, 72 cases) over a median follow-up of 4.6 years.
- Statin use was associated with 36% lower risk for liver cancer (adjusted HR [aHR], 0.64; 95% CI, 0.39-1.07).
- The reduction in risk was most marked for HCC (aHR, 0.48; 95% CI, 0.24-0.94) but not for IBDC (aHR, 1.09; 95% CI, 0.45-2.64).
- Risk of confounders.